Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Jun;80(3):467-73.
doi: 10.1111/j.1365-2249.1990.tb03311.x.

Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice

Affiliations

Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice

H Carlsten et al. Clin Exp Immunol. 1990 Jun.

Abstract

The influence of oestrogen on the lupus disease in MRL/l mice has been investigated. Adult, castrated male and female MRL/l mice were administered with s.c. injections of 3.2 micrograms of 17 beta-oestradiol twice a week. The results clearly demonstrate that a relatively small dose of oestrogen is a potent accelerator of the lupus disease in this mouse strain. Thus, administration of oestrogen accelerates glomerulonephritis, lymphoproliferation and mortality. Our results also indicate that oestrogen exerts a dual effect on the immune system of MRL/l mice by depression of antigen-specific and mitogen-induced T cell responses as well as enhancement of polyclonal B cell activation and autoantibody formation. In addition, even short-term administration of oestrogen in the preclinical phase of the disease resulted in long-lasting effects as evaluated by reduced longevity and aggravation of renal disease.

PubMed Disclaimer

References

    1. J Immunol Methods. 1983 Dec 16;65(1-2):109-21 - PubMed
    1. Clin Immunol Immunopathol. 1984 Apr;31(1):65-77 - PubMed
    1. Immunol Rev. 1984 Apr;78:159-83 - PubMed
    1. Endocr Rev. 1984 Summer;5(3):435-55 - PubMed
    1. Clin Exp Immunol. 1984 Oct;58(1):7-12 - PubMed

Publication types